Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia
Article first published online: 26 OCT 2005
Copyright © 2005 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 20, Issue 11, pages 1020–1027, November 2005
How to Cite
Kennedy, J., Deberdt, W., Siegal, A., Micca, J., Degenhardt, E., Ahl, J., Meyers, A., Kaiser, C. and Baker, R. W. (2005), Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int. J. Geriat. Psychiatry, 20: 1020–1027. doi: 10.1002/gps.1397
- Issue published online: 26 OCT 2005
- Article first published online: 26 OCT 2005
- Manuscript Accepted: 25 MAY 2005
- Manuscript Received: 10 FEB 2005
- Eli Lilly and Company, Indianapolis, IN, USA
- Alzheimer's disease;
This was an exploratory study of olanzapine as potential treatment for improvement in cognition in patients with Alzheimer's disease without prominent psychobehavioral symptoms.
Non-psychotic/non-agitated patients (n = 268) with Alzheimer's disease, who had baseline Mini-Mental State Examination (MMSE) scores of 14–26 were randomized to treatment with olanzapine (2.5 to 7.5 mg/d) or placebo for 26 weeks. The primary objectives were to determine if treatment with olanzapine improved cognition as indexed by the Alzheimer's disease Assessment Scale for Cognition (ADAS-Cog) and the Clinician's Interview-Based Impression of Change (CIBIC) after 26 weeks of therapy.
Patients treated with olanzapine vs placebo experienced significant worsening ADAS-Cog scores at weeks 12 (p = 0.03) and 26 (p = 0.004). Changes in CIBIC scores were not significantly different between treatment groups at either assessment. A post hoc analysis revealed that olanzapine-treated patients with more cognitive impairment at baseline (MMSE scores of 14–18) (n = 35) experienced significantly greater deterioration in ADAS-Cog performance than patients in the placebo group (n = 24; p < 0.001); whereas in patients with less cognitive impairment (n = 78, baseline MMSE scores of 23–26) between-group ADAS-Cog changes were not significant.
In this 26-week study non-psychotic/non-agitated patients with Alzheimer's disease treated with olanzapine experienced significant worsening of cognition as compared to placebo. Copyright © 2005 John Wiley & Sons, Ltd.